Cannabis Effects on Antiretroviral Therapy Pharmacokinetics and Neurotoxicity

HIV Clinical Trial

Official title:

Cannabis Effects on Antiretroviral Therapy Pharmacokinetics and Neurotoxicity

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04800159
• Other study ID #: DA050491
• Status: Recruiting
• Phase: Phase 2
• Start date: February 19, 2021
• Est. completion date: April 30, 2025

Study information

• Verified date: October 2023
• Source: University of California, San Diego
• Contact: Roberto Gallardo
• Phone: 619-543-5000
• Email: hnrprecruitment[@]ucsd.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will address whether cannabis affects antiretroviral therapy (ART) drug concentrations, mood, and thinking. The project will have two phases. Phase 1 is an observational study, in which 120 people will be assessed to evaluate the effects of chronic cannabis use on ART drug concentrations, mood, and thinking. In Phase 2, the study will administer cannabis (or placebo) to 40 people to examine its acute effects on ART drug concentrations.

Description:

People with human immunodeficiency virus (HIV) commonly use cannabis but whether cannabis affects the antiretroviral therapy (ART) that treats HIV is not well known. Cannabis can inhibit the activity of enzymes that metabolize and eliminate ART drugs from the body, which could result in higher concentrations of ART drugs in the body. Cannabis may also affect the distribution of ART drugs into the brain, which could have both beneficial (e.g., better HIV control) and detrimental (e.g., toxicity) effects. The effects of cannabis may are likely influenced by factors like how much is used (e.g., light vs. heavy use) and the route of use (e.g., smoked vs. ingested). This study will address whether cannabis affects ART concentrations in blood and cerebrospinal fluid as well as mood, and thinking. The project will have two phases. Phase 1 is an observational study, in which 120 people will be assessed once to evaluate the effects of chronic cannabis use on ART drug concentrations, mood, and thinking. In Phase 2, the study will administer cannabis (or placebo) to 40 people to examine its acute effects on ART drug concentrations.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: April 30, 2025
• Est. primary completion date: January 30, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria for All Visits:

1. Age 18 or older;

2. Capacity to provide informed consent;

3. Presence of HIV infection by a standard diagnostic test;

4. On a stable ART regimen for at least 1 month and with a suppressed viral load by self-report;

5. Willing to abstain from cannabis for at least 24 hours prior to the Phase 1 assessment.

6. Willing to abstain from grapefruit juice consumption for 4 weeks prior to the Phase 1 assessment.

Additional Inclusion Criteria for participation in Phase 2 (interventional):

1. Treatment with an integrase inhibitor (i.e. dolutegravir);

2. Use of cannabis in the past two years without a severe adverse reaction (e.g., disorientation, paranoia, or hallucinations). The two-year cutoff is to ensure exposure to modern cannabis, which is more likely to match the drug concentrations administered in this study;

3. Willing to refrain from driving or operating heavy machinery after the visit; and

4. Willing to abstain from cannabis for at least 48 hours prior to the cannabis administration visits.

5. Willing to abstain from grapefruit juice consumption for 4 weeks prior to cannabis administration and during the administration visits

Exclusion Criteria for All Visits:

1. Traumatic brain injury, including head injury with loss of consciousness for greater than 30 minutes or resulting in neurologic complications;

2. Dementia, including Alzheimer's disease;

3. History of stroke with residual neurologic sequelae;

4. History of seizure disorder with a seizure in the past year;

5. Severe psychiatric disorder (e.g., schizophrenia) that might make the person's participation in the study unsafe;

6. Substance or alcohol use disorder in the past 3 months;

7. Contraindications to lumbar puncture for those consenting to lumbar puncture (e.g., coagulopathy).

Additional Exclusion Criteria for participation in the cannabis administration visits:

1. Younger than 21 years (due to safety of cannabis in children and adolescents);

2. Respiratory condition that would be exacerbated by inhaling vaporized cannabis (e.g., asthma or chronic obstructive pulmonary disease) or limited lung capacity that would prevent the individual from performing the Foltin puff procedure;

3. History of cardiovascular disease, including myocardial infarction;

4. Uncontrolled hypertension with systolic blood pressure greater than 160 mm Hg or a diastolic blood pressure greater than 100 mm Hg prior to study product administration;

5. Resting pulse greater than 100 beats per minute prior to study product administration;

6. Pregnancy as determined by a human chorionic gonadotropin urine test, women who are lactating, or unwillingness to prevent pregnancy during the cannabis administration portion of the study (using birth control in women of child-bearing age). Acceptable methods of birth control are: oral contraceptive pills, diaphragm, condom, progestin implant, intrauterine contraceptive device, sterilization, etc;

7. Active opportunistic infection or malignancy requiring treatment;

8. Unintentional loss of 10% or more of body weight during the previous 6 months;

9. CD4+ T-cell count less than 200 cells/µL;

10. Estimated glomerular filtration rate < 30 mL/minute, indicative of renal dysfunction;

11. Hepatic transaminases > 2 times the upper limit of normal;

12. Current severe depressive symptoms (BDI-II score = 31) or suicidal ideation;

13. Known sensitivity to acetaminophen (the probe for UGT activity);

14. Current use of substances that could have adverse interactions with acetaminophen or cannabis (e.g., grapefruit juice).

Related Conditions & MeSH terms

• Cannabis Use
• HIV
• Marijuana Abuse
• Neurotoxicity Syndromes

Intervention

Drug:
• THC Cannabis
Vaporization of cannabis
• CBD Cannabis
Vaporization of cannabis
• Placebo
Vaporization of placebo

Locations

Country	Name	City	State
United States	Ucsd Hnrp-Cmcr	San Diego	California

Sponsors (2)

Lead Sponsor	Collaborator
University of California, San Diego	Center for Medicinal Cannabis Research

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	1a i. Antiretroviral therapy (ART) drug concentration in blood	This will be done separately for participants who use ART drugs that are predominantly metabolized by cytochrome P450 (CYP) or uridine 5'-diphospho-glucuronosyltransferase (UGT) (estimated N=60 in each).	Cross-sectional; measured before ART ingestion
Primary	1a ii. Cerebrospinal fluid (CSF)/plasma ratio of ART drug concentrations	This will be done separately for CYP and UGT groups (estimated N=60 in each).	Cross-sectional; measured before ART ingestion
Primary	1a iii. Change in ART drug concentrations in blood	This will be done separately for CYP and UGT groups (estimated N=60 in each).	2 hours; measured before ART ingestion and at 2 hours after the ART ingestion
Primary	1a iv. Change in CSF/plasma ratio of ART drug concentrations	This will be done separately for CYP and UGT groups (estimated N=60 in each).	2 hours; measured before ART ingestion and at 2 hours after the ART ingestion
Primary	1b i. Effects of placebo, THC, and CBD on ART drug concentration	The investigators will use a mixed effects model to assess effects of acute cannabis treatment (placebo, THC, or CBD: N=40) on the area under the time-drug concentration curve.	5 hours
Primary	1b ii. Effects of placebo, THC and CBD on the CSF/plasma ratio of ART drug concentrations	The investigators will use a mixed effects model to assess effects of acute cannabis treatment (placebo, THC, or CBD: N=40) on CSF/plasma ratio of ART drug concentrations	5 hours
Primary	1b iii. Comparison between the effects of placebo and THC on ART pharmacokinetics and between the effects of placebo and CBD on ART pharmacokinetics	Comparison of the the area under the time-concentration curve of ART pharmacokinetics for placebo and THC and placebo and CBD (n=40). The effect size will be measured as the standardized difference in mean outcomes between any two groups (Cohen's d).	3 to 11 days
Primary	1b iv. Comparison between the effects of placebo and CBD on the CSF/plasma ratio of ART drug concentrations and between the effects of placebo and THC on the CSF/plasma ratio of ART drug concentrations	Comparison of the the CSF/plasma ratio of ART drug concentrations with placebo and CBD and with placebo and THC (n=40). The effect size will be measured as the standardized difference in mean outcomes between any two groups (Cohen's d).	3 to 11 days
Primary	2a. Effects of chronic cannabis use on the CSF/serum albumin ratio and P-glycoprotein (P-gp) expression.	Multivariate linear regression will be used to regress markers of blood-brain barrier integrity and P-gp on cannabis use (n = 120), then ART drug concentrations on blood-brain barrier integrity and P-gp separately for the UGT and CYP groups	3 to 11 days
Primary	2b. Examine the correlation between ART concentration in CSF and blood during placebo treatment compared to THC and CBD administration.	The investigators will use a mixed effects model to evaluate the effects of cannabis on the correlation between ART concentration in CSF and blood (n = 40).	3 to 11 days
Primary	2c. Effects of THC or CBD on uridine 5'-diphospho-glucuronosyltransferase (UGT) activity compared to placebo.	The investigators will use a mixed effects model to examine the effects of drug treatment on UGT metabolism (n = 40).	3 to 11 days
Primary	3a. i. Correlation between CD4+ T-cell count and ART drug concentration.	Multivariable linear regressions will be used for testing correlation between CD4+ T-cell count and ART drug concentration (N=60 in each UGT and CYP groups).	Up to 5 weeks: baseline to administration visits
Primary	3a. ii. Correlation between HIV DNA and ART drug concentration.	Multivariable logistic regressions will be used for testing correlation between HIV DNA and ART drug concentration (N=60 in each UGT and CYP groups).	Up to 5 weeks: baseline to administration visits
Primary	3b i. Effects of cannabis use on the correlation between ART and neurocognitive performance.	The total cognitive outcome from the National Institutes of Health Toolbox will be regressed in multivariable models on ART drug concentration and cannabis use, their interaction, and known confounders and relevant covariates. Values range from 0 to 100 with lower values being worse.	3 to 11 days
Primary	3b ii. Effects of cannabis use on the correlation between ART and depression.	Depression (measured with the Beck Depression Inventory-II) will be regressed in multivariable models on ART drug concentration and cannabis use, their interaction, and known confounders and relevant covariates.	3 to 11 days
Primary	3b iii. Effects of cannabis use on the correlation between ART and emotional health.	The National Institutes of Health Toolbox-Emotional Battery outcome, Negative Affect, will be regressed in multivariable models on ART drug concentration and cannabis use, their interaction, and known confounders and relevant covariates. This measure ranges between 0 and 100 with higher values reflecting more Negative Affect.	3 to 11 days
Primary	3b iv. Effects of cannabis use on the correlation between ART and emotional health.	The National Institutes of Health Toolbox-Emotional Battery outcome, Social Satisfaction, will be regressed in multivariable models on ART drug concentration and cannabis use, their interaction, and known confounders and relevant covariates. This measure ranges between 0 and 100 with lower values reflecting worse Social Satisfaction.	3 to 11 days
Primary	3b v. Effects of cannabis use on the correlation between ART and emotional health.	The National Institutes of Health Toolbox-Emotional Battery outcome, Psychological Wellbeing, will be regressed in multivariable models on ART drug concentration and cannabis use, their interaction, and known confounders and relevant covariates. This measure ranges between 0 and 100 with lower values reflecting worse Psychological Wellbeing.	3 to 11 days
Primary	3b vi. Effects of cannabis use on the correlation between ART and neurotoxicity.	A measure of neurotoxicity (mitochondrial DNA) will be regressed in multivariable models on ART drug concentration and cannabis use, their interaction, and known confounders and relevant covariates.	3 to 11 days
Primary	3b vii. Effects of cannabis use on the correlation between ART and neurotoxicity.	A measure of neurotoxicity (8-hydroxydeoxyguanosine) will be regressed in multivariable models on ART drug concentration and cannabis use, their interaction, and known confounders and relevant covariates.	3 to 11 days
Primary	3b viii. Effects of cannabis use on the correlation between ART and neurotoxicity.	A measure of neurotoxicity (F2-isoprostane) will be regressed in multivariable models on ART drug concentration and cannabis use, their interaction, and known confounders and relevant covariates.	3 to 11 days
Secondary	1b v. Comparison between the effects of THC and CBD on ART pharmacokinetics.	Comparison of the treatment arm to the the area under the time-concentration curve of ART pharmacokinetics (n=40).	3 to 11 days
Secondary	1b vi. Comparison between the effects of THC and CBD on the CSF/plasma ratio of ART drug concentrations.	Comparison of treatment arm to the CSF/plasma ratio of ART drug concentrations.	3 to 11 days